IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

Cystic Fibrosis Clinical Trial

Official title:

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02918409
• Other study ID #: SAAVED15A0
• Status: Completed
• Phase: Phase 4
• Start date: August 26, 2016
• Est. completion date: November 22, 2021

Study information

• Verified date: March 2023
• Source: National Jewish Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find the safest and most effective way to administer IV antibiotics to treat acute pulmonary exacerbations (APEs) in patients with cystic fibrosis (CF) that are caused by pathogens, like Pseudomonas aeruginosa. This study will test the safety and effectiveness of two commonly prescribed IV antibiotics: tobramycin and colistin. Though regularly used, not much is known about how these drugs compare with each other in terms of their toxicities, both during short term treatment of an APE and after many treatment courses with these drugs over many years. There are currently no guidelines on the safest and most effective antibiotics to use when treating APEs. We will study kidney function, sputum cultures, and treatment outcomes in patients receiving routine administration of one of these two IV antibiotics. We will also test these outcomes in patients receiving a less frequent dosing schedule for IV colistin. The hope is that this new schedule for IV colistin, which is twice a day and adjusted based on blood and urine tests, will reduce harmful side effects, such as kidney damage, while still being a powerful treatment against CF microbial pathogens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: November 22, 2021
• Est. primary completion date: September 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 18 years of age at Visit 1.

2. Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

• Sweat chloride equal or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test.

• Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

• Abnormal nasal potential difference (NPD) as measured by a change in NPD in response to a low chloride solution and isoproterenol of less than -5 mV.

3. Documentation of the presence of an acute pulmonary exacerbation, based on CF Foundation guidelines, as diagnosed by a faculty member of the Denver Adult CF Program.

4. Respiratory culture(s) demonstrating evidence of Pseudomonas aeruginosa or Achromobacter species airway infection.

5. Subject is able to produce sputum, undergo phlebotomy, and provide written consent.

6. The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment. Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms. If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin.

Exclusion Criteria:

1. Concomitant administration of bactrim (due to effects on creatinine).

2. Concomitant administration of inhaled colistin for patients in the colistin PK arm, as this will create inaccuracies in colistin sputum concentration measurements.

3. Patients being treated for B. cepacia, due to colistin resistance by the pathogen.

4. Presence of chronic renal insufficiency, with abnormal baseline creatinine >1.2mg/dL.

5. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.

6. Inability to perform reproducible spirometry.

7. Inability to expectorate sputum. -

Related Conditions & MeSH terms

• Cystic Fibrosis

Intervention

Drug:
• Colistin

• Tobramycin

Locations

Country	Name	City	State
United States	National Jewish Health	Denver	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
National Jewish Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute Change in Forced Expiratory Volume at One Second (FEV1) % Predicted Between Study Arms With Acute Pulmonary Exacerbation (APE) Treatment	absolute change in forced expiratory volume at one second (FEV1) % predicted, or percent predicted FEV1, between study arms with acute pulmonary exacerbation (APE) treatment	up to 14 days, from beginning to end of APE treatment
Primary	Rate of Occurrence of the Development of Acute Kidney Injury (AKI) During APE Treatment		up to 14 days, from beginning to end of APE treatment
Secondary	Time to Achievement of Steady State With Pharmacokinetic (PK)-Adjusted Colistin Therapy		up to 14 days, from beginning to end of APE treatment
Secondary	Longitudinal Differences in Exacerbation Rates Between Tobramycin and Colistin Use as Seen in Readmission Rate	time to next admission for exacerbation measured in days when comparing of different antibiotic therapies	from the beginning of APE treatment to 12 months after APE treatment
Secondary	Differences in Occurrences of Neurotoxicity and Ototoxicity Related Side Effects Between Study Arms as Reported by Treating Physician(s)	absolute occurrences of adverse event rates are being compared between treatment groups using logistic regression, adjusting for age, co-administration of medications such as vancomycin and trimethoprim-sulfamethoxazole, baseline FEV1, admits in the previous year, and diagnosis of CF related diabetes (CFRD) as covariates.	up to 14 days, from beginning to end of APE treatment
Secondary	Measurement of Pharmacokinetics of Colistin's Active Metabolites in a Broad CF Population Through Peak, Trough, and Midpoint Blood Draws		up to 14 days, from beginning to end of APE treatment
Secondary	Comparison of Plasma Pharmacokinetics of Colistin's Active Metabolites With Levels Achieved in the Sputum, in Order to Calculate Epithelial Lining Fluid Concentrations, Through Mass Spectrometry		up to 14 days, from beginning to end of APE treatment
Secondary	Novel Biomarkers of Nephrotoxic AKI, Prior to Serum Creatinine Increases, Based on Urine Protein:Creatinine Ratios		up to 14 days, from beginning to end of APE treatment
Secondary	Novel Biomarkers of Nephrotoxic AKI, Prior to Serum Creatinine Increases, Based on the Urine Biomarker Nephrocheck® Point-of-care Assay		up to 14 days, from beginning to end of APE treatment